Telix Pharmaceuticals is highlighting studies set to be presented at the European Association of Nuclear Medicine meeting to be held September 9-13 in Vienna.
Specifically, new data will be presented in on oral session on September 10 from the company's phase III trial evaluating the sensitivity and specificity of zirconium 89 (Zr-89) TLX250 PET/CT to detect clear cell renal cell cancer (ccRCC) in adult patients with indeterminate renal masses, Telix said.
In addition, the following Telix initiatives will also be presented:
- A phase III study of the company's TLX591 investigational prostate cancer therapy
- A session covering AI segmentation and primary characterization of prostate cancer lesions using models trained on gallium 68 (Ga-68) PSMA-11 PET/CT image datasets
- The Nobody Left Behind (NOBLE) Registry of Telix's SPECT-based prostate cancer imaging agent TLX599-CDx
- A preclinical evaluation of carbonic anhydrase IX (CAIX)-targeted lutetium-177 radionuclide therapy in combination with immune checkpoint inhibition
